Danaher Corporation $DHR Shares Sold by Douglass Winthrop Advisors LLC

Key Points

• Douglass Winthrop Advisors LLC has reduced its stake in Danaher Corporation by 3.3%, selling 2,515 shares, and now holds 73,468 shares valued at approximately $15.06 million.
• Numerous institutional investors, including Sax Wealth Advisors LLC and AlphaQuest LLC, have significantly increased their stakes in Danaher during the same period.
• Analysts display a favorable outlook on Danaher, with a consensus target price of $247.61 and a majority rating of "Moderate Buy" among 20 analysts reviewing the stock.

Douglass Winthrop Advisors LLC lowered its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 3.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 73,468 shares of the conglomerate's stock after selling 2,515 shares during the period. Douglass Winthrop Advisors LLC's holdings in Danaher were worth $15,061,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Sax Wealth Advisors LLC raised its position in Danaher by 4.1% during the first quarter. Sax Wealth Advisors LLC now owns 3,393 shares of the conglomerate's stock worth $695,000 after acquiring an additional 133 shares during the last quarter. AlphaQuest LLC raised its position in shares of Danaher by 3,797.0% in the first quarter. AlphaQuest LLC now owns 6,430 shares of the conglomerate's stock valued at $1,318,000 after buying an additional 6,265 shares during the last quarter. Blue Whale Capital LLP raised its position in shares of Danaher by 5.0% in the first quarter. Blue Whale Capital LLP now owns 346,246 shares of the conglomerate's stock valued at $70,980,000 after buying an additional 16,500 shares during the last quarter. Kestra Advisory Services LLC raised its position in shares of Danaher by 3.9% in the first quarter. Kestra Advisory Services LLC now owns 90,178 shares of the conglomerate's stock valued at $18,486,000 after buying an additional 3,413 shares during the last quarter. Finally, Portland Investment Counsel Inc. raised its position in shares of Danaher by 1.9% in the first quarter. Portland Investment Counsel Inc. now owns 54,754 shares of the conglomerate's stock valued at $11,225,000 after buying an additional 1,000 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.

Wall Street Analysts Forecast Growth

DHR has been the subject of a number of analyst reports. UBS Group cut their price objective on shares of Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a research report on Wednesday, July 23rd. Guggenheim reissued a "buy" rating and issued a $250.00 price objective on shares of Danaher in a research report on Wednesday, July 23rd. Scotiabank raised shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price objective for the company in a research report on Friday, July 11th. Deutsche Bank Aktiengesellschaft cut their price objective on shares of Danaher from $240.00 to $235.00 in a research report on Thursday, June 5th. Finally, Barclays reaffirmed an "overweight" rating and set a $225.00 price target (up previously from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Seventeen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $247.61.

Danaher Trading Down 0.8%

DHR traded down $1.59 during trading on Thursday, hitting $203.41. 921,280 shares of the company's stock were exchanged, compared to its average volume of 4,175,272. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $279.90. The stock has a 50 day moving average price of $201.23 and a 200 day moving average price of $199.46. The firm has a market cap of $145.65 billion, a P/E ratio of 43.29, a price-to-earnings-growth ratio of 2.88 and a beta of 0.73.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The company had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. During the same period in the previous year, the firm earned $1.72 earnings per share. Danaher's revenue for the quarter was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, analysts expect that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Insider Buying and Selling at Danaher

In other news, Director Teri List sold 2,778 shares of the company's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the transaction, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 11.10% of the company's stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.